Monitor for subsequent PCT or non-provisional filings and any clinical updates on the osteoarthritis pilot study — the patent itself is a procedural step with no near-term stock catalyst.
Price Chart
Executive Summary
Creative Medical Technology Holdings filed a provisional patent application covering its Ultrasome cell-free regenerative medicine platform, expanding IP protection beyond the initial osteoarthritis program. The filing is a routine IP step with no clinical or regulatory catalyst — it does not change the company's near-term outlook or financial position.
Key Facts
- Filed a new U.S. provisional patent application for the Ultrasome platform, covering composition, potency, manufacturing, stability, delivery, and therapeutic applications.
- The filing builds on a previously announced pilot study in knee osteoarthritis (April 2026) that reported ~93% of participants showed clinically meaningful improvements with no serious adverse events.
- The provisional application has not been examined by the USPTO; no assurance of patent issuance or claim scope.
- Ultrasome is derived from the Olastrocel platform, with manufacturing data maintained in an FDA Drug Master File (not FDA approval).
Financial Impact
No financial figures disclosed; patent filing is a routine IP action with no immediate revenue or cost impact.
Risk Factors
- Provisional patent applications do not guarantee patent issuance or commercially meaningful protection.
- The company is clinical-stage with no approved products; IP alone does not create value without clinical and regulatory success.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364017 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | SC 13D | $0.9464 $0.9200 | ▼ −2.79% | ▼ −3.46% | $0.7120 (−24.77%) |
Sep 25, 2026 4w ago | 8-K | $1.01 $0.9652 | ▼ −4.44% | ▼ −4.25% | $0.7120 (−29.50%) |
Sep 17, 2026 5w ago | Press Release | $0.8775 $0.9659 | ▲ +10.07% | ▲ +10.19% | $0.7120 (−18.86%) |
Aug 20, 2026 9w ago | Press Release | $1.28 $1.31 | ▲ +2.34% | ▲ +1.93% | $0.7120 (−44.37%) |
Jul 1, 2026 16w ago | Press Release | $1.27 $1.21 | ▼ −4.72% | ▼ −4.59% | $0.7120 (−43.94%) |
Jun 30, 2026 16w ago | Press Release | $1.45 $1.27 | ▲ +12.41% | ▲ +12.28% | $0.7120 (+50.90%) |
Jun 26, 2026 17w ago | S-1/A | $0.8102 $1.45 | ▼ −78.97% | ▼ −78.19% | $0.7120 (+12.12%) |
Jun 25, 2026 17w ago | S-1 | $1.20 $0.8102 | ▼ −32.48% | ▼ −34.13% | $0.7120 (−40.67%) |
Jun 22, 2026 18w ago | Press Release | $1.93 $1.97 | ▲ +2.07% | ▲ +3.52% | $0.7120 (−63.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers